Individualized medicine in the treatment of human prostate cancer using laser-captured microdissection technique

2014 Fiscal Year Final Research Report

• Project/Area Number: 24592377
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: The University of Tokyo
• Principal Investigator: FUJIMURA Tetsuya 東京大学, 医学部附属病院, 講師 (50376448)
• Co-Investigator(Kenkyū-buntansha): YUKIO Homma 東京大学, 医学部附属病院, 教授 (40165626) ; SATOSHI Inoue 東京大学, 医学部附属病院, 特任教授 (40251251) ; 浦野 友彦 東京大学, 医学部附属病院, 講師 (20334386)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 前立腺癌 / 内分泌療法 / アンドロゲン / エストロゲン / 幹細胞

Outline of Final Research Achievements

We developed models to predict CF using biopsy samples from a training set of 46 and independent validation set of 30 patients with treatment-naïve PC with bone metastasis. Cancerous and stromal tissues were separately collected by laser-captured microdissection.Logistic analyses to predict PSA recurrence showed an area under the curve (AUC) of 1.0 in both sets for Sox2, Her2, and CRP expression in cancer cells; AR and ERα expression in stromal cells; and clinical parameters. We identified 10 prognostic factors for cancer-specific survival (CSS): Oct1, TRIM36, Sox2, and c-Myc expression in cancer cells; AR, Klf4, and ERα expression in stromal cells; and PSA, Gleason score, and extent of disease. On the basis of these factors, patients were divided into favorable-, intermediate-, and poor-risk groups according to the number of factors present. Five-year CSS rates for the 3 groups were 90%, 32%, and 12% in training set and 75%, 48%, and 0% in validation set, respectively.

Free Research Field

前立腺癌